Table 4.
C max/LCRD Ratios for Metabolomics and Transcriptomics Experiments to Determine Likelihood of Therapeutic Doses Resulting in High Enough Exposure Levels to Cause Observed Responses in Humans
| Chemical | Metabolomics BMC LCRD (µM) | Transcriptomics BMC LCRD (µM) | Reference Human Plasma Concentrations in µMa | Metabolomics Cmax/LCRD | Transcriptomics Cmax/LCRD |
|---|---|---|---|---|---|
| Chlorpromazine | 0.65 | 0.70 | 0.47 | 0.73 | 0.68 |
| KCl | 3.78 | 159.38 | — | — | — |
| Rifampicin | 1.23 | 8.56 | 13.00 | 10.53 | 1.52 |
| Ritonavir | 0.20 | 0.32 | 15.50 | 75.98 | 47.84 |
| Sucrose | 20.02 | 72.74 | — | — | — |
| Tamoxifen | 0.54 | 1.20 | 0.32 | 0.60 | 0.27 |
a
Reference human plasma concentrations were obtained from Drug Matrix, Goodman & Gilman, and the Physician’s Desk Reference.